J. Insulin glargine. Drugs 63, 1743–1778 (2003). Article CAS PubMed Google Scholar Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104–2114 (2012). Article CAS PubMed PubMed Central Google ...
There are a total of 223 marketed long-acting formulations [7]. Figure1a illustrates the classification of approved LAIs based on the route of administration and 1b therapeutic areas. The current trend shows an increase in chronic disease numbers that require treatment for the long term, including...
J. Insulin glargine. Drugs 63, 1743–1778 (2003). Article CAS PubMed Google Scholar Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104–2114 (2012). Article CAS PubMed PubMed Central Google ...
ProductBasalin®(insulin glargine injection) Basalin® is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin® is...
GLP-1 agonists are not used to treat insulin-dependent ortype 1 diabetes(a condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) and diabeticketoacidosis(increased ketones in the blood or urine). ...
Therefore, the current study aimed to evaluate trends in prescribing (uptake), treatment adherence, and costs of (newer) insulin analogs (e.g., insulin detemir and insulin glargine). METHODS: A drug-utilization analysis was conducted based on using daily- practice prescription data from IADB.nl...
Please Wait Applying Filters...X PHARMACOMPASS Grow Your Pharma Business Digitally Market Place Post Enquiry PHARMACOMPASS Grow Your Pharma Business Digitally Find Suppliers (API/FDF) Services Search for Service - Analytical - Analytical Method Development - Biologic Drugs - Capillary ...
A gender-specific drug utilization study was performed in the Campania region, Southern Italy. Data were based on outpatient drug prescriptions collected from administrative databases. The study population included all patients with at least one drug pre
of all hypoglycemia between children treated with insulin glargine and NPH insulin.;Secondary Objective: Los objetivos secundarios son comparar la insulina glargina y la insulina NPH en términos de:-Índices de los tipos específicos de hipoglucemias: sintomática, severa, nocturna, nocturna...
Since the excessive classifications and the small sample size of each classification, EEs type was divided into CUA-related and CUA-unrelated to facilitate the analysis. Model Choice describes different analysis model in EEs studies. Funding means whether the identified EEs were funded by government,...